Next Article in Journal
Correction: Ratnayake et al. Assessment of Breast Cancer Surgery in Manitoba: A Descriptive Study. Curr. Oncol. 2021, 28, 581–592
Previous Article in Journal
Reflecting on Palliative Care Integration in Canada: A Qualitative Report
Article

Discrimination of Cancer Stem Cell Markers ALDH1A1, BCL11B, BMI-1, and CD44 in Different Tissues of HNSCC Patients

1
Department of Otolaryngology, University Hospital, LMU Munich, 81377 Munich, Germany
2
Institute of Pathology, Faculty of Medicine, LMU Munich, 81377 Munich, Germany
3
Clinical Cooperation Group “Personalized Radiotherapy in Head and Neck Cancer”, Helmholtz Zentrum München, 85764 Neuherberg, Germany
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(4), 2763-2774; https://doi.org/10.3390/curroncol28040241
Received: 31 May 2021 / Revised: 3 July 2021 / Accepted: 11 July 2021 / Published: 19 July 2021
(This article belongs to the Special Issue New Frontiers in Head and Neck Oncology)
Cancer stem cells (CSCs) are accountable for the progress of head and neck squamous cell carcinoma (HNSCC). This exploratory study evaluated the expression of molecular CSC markers in different tissues of HNSCC patients. Tissue specimens of primary tumor, lymph node metastases and macroscopically healthy mucosa of 12 consecutive HNSCC patients, that were treated with surgery and adjuvant radio(chemo)therapy upon indication, were collected. Samples were assessed for the expression of p16 as a surrogate for HPV-related disease and different molecular stem cell markers (ALDH1A1, BCL11B, BMI-1, and CD44). In the cohort, seven patients had HPV-related HNSCC; six thereof were oropharyngeal squamous cell carcinoma. While expression of BMI-1 and BCL11B was significantly lower in healthy mucosa than both tumor and lymph node metastasis, there were no differences between tumor and lymph node metastasis. In the HPV-positive sub-cohort, these differences remained significant for BMI-1. However, no significant differences in these three tissues were found for ALDH1A1 and CD44. In conclusion, this exploratory study shows that CSC markers BMI-1 and BCL11B discriminate between healthy and cancerous tissue, whereas ALDH1A1 and CD44 were expressed to a comparable extent in healthy mucosa and cancerous tissues. View Full-Text
Keywords: CSCs; histopathology; HNSCC; tumor; lymph node; mucosa CSCs; histopathology; HNSCC; tumor; lymph node; mucosa
Show Figures

Figure 1

MDPI and ACS Style

Sharaf, K.; Lechner, A.; Haider, S.P.; Wiebringhaus, R.; Walz, C.; Kranz, G.; Canis, M.; Haubner, F.; Gires, O.; Baumeister, P. Discrimination of Cancer Stem Cell Markers ALDH1A1, BCL11B, BMI-1, and CD44 in Different Tissues of HNSCC Patients. Curr. Oncol. 2021, 28, 2763-2774. https://doi.org/10.3390/curroncol28040241

AMA Style

Sharaf K, Lechner A, Haider SP, Wiebringhaus R, Walz C, Kranz G, Canis M, Haubner F, Gires O, Baumeister P. Discrimination of Cancer Stem Cell Markers ALDH1A1, BCL11B, BMI-1, and CD44 in Different Tissues of HNSCC Patients. Current Oncology. 2021; 28(4):2763-2774. https://doi.org/10.3390/curroncol28040241

Chicago/Turabian Style

Sharaf, Kariem, Axel Lechner, Stefan P. Haider, Robert Wiebringhaus, Christoph Walz, Gisela Kranz, Martin Canis, Frank Haubner, Olivier Gires, and Philipp Baumeister. 2021. "Discrimination of Cancer Stem Cell Markers ALDH1A1, BCL11B, BMI-1, and CD44 in Different Tissues of HNSCC Patients" Current Oncology 28, no. 4: 2763-2774. https://doi.org/10.3390/curroncol28040241

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop